|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 6/13
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
50,050,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.00001 - $0.00001 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625,757 |
| Total Buy Value |
$0 |
$0 |
$0 |
$38,218,360 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
35 |
| Total Shares Sold |
0 |
0 |
0 |
7,293,025 |
| Total Sell Value |
$0 |
$0 |
$0 |
$13,624,564 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
12 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Otto Dawn Parsell |
Sr VP, Clinical Development |
• – – |
2019-01-07 |
4 |
AS |
$23.27 |
$15,475 |
D/D |
(665) |
0 |
|
- |
|
| Lockey Claire |
Chief Dev. Officer and Sr. VP |
• – – |
2019-01-02 |
4 |
S |
$23.59 |
$16,136 |
D/D |
(684) |
0 |
|
- |
|
| Veitinger Klaus R Dr |
Director |
– • – |
2018-12-27 |
4 |
AS |
$23.74 |
$34,214 |
I/I |
(1,440) |
97,444 |
|
- |
|
| Veitinger Klaus R Dr |
Director |
– • – |
2018-12-27 |
4 |
AS |
$23.63 |
$23,559 |
D/D |
(997) |
39,436 |
|
- |
|
| Veitinger Klaus R Dr |
Director |
– • – |
2018-12-27 |
4 |
OE |
$0.80 |
$798 |
D/D |
997 |
40,433 |
|
- |
|
| Veitinger Klaus R Dr |
Director |
– • – |
2018-12-26 |
4 |
AS |
$24.97 |
$163,803 |
I/I |
(6,560) |
98,184 |
|
- |
|
| Veitinger Klaus R Dr |
Director |
– • – |
2018-12-26 |
4 |
AS |
$24.97 |
$81,252 |
D/D |
(3,254) |
39,436 |
|
- |
|
| Veitinger Klaus R Dr |
Director |
– • – |
2018-12-26 |
4 |
OE |
$0.80 |
$2,603 |
D/D |
3,254 |
42,690 |
|
- |
|
| Coufal Sandra I |
Director |
– • • |
2018-12-26 |
4 |
AS |
$25.08 |
$85,272 |
I/I |
(3,400) |
21,725 |
|
- |
|
| Klaerner Gerrit |
President and CEO |
• • – |
2018-12-26 |
4 |
AS |
$25.02 |
$50,040 |
I/I |
(2,000) |
144,984 |
|
- |
|
| Klaerner Gerrit |
President and CEO |
• • – |
2018-12-26 |
4 |
AS |
$25.02 |
$50,040 |
D/D |
(2,000) |
703,488 |
|
- |
|
| Lockey Claire |
Chief Dev. Officer and Sr. VP |
• – – |
2018-12-26 |
4 |
AS |
$25.06 |
$250,600 |
D/D |
(10,000) |
0 |
|
- |
|
| Lockey Claire |
Chief Dev. Officer and Sr. VP |
• – – |
2018-12-26 |
4 |
OE |
$0.80 |
$8,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Parker Geoffrey M. |
Chief Fin. Officer and Sr. VP |
• – – |
2018-11-13 |
4 |
B |
$29.72 |
$148,600 |
D/D |
5,000 |
65,000 |
2.74 |
- |
|
| Sibling Co-Investment Llc |
possible member of 10% group |
– – • |
2018-07-02 |
4 |
B |
$19.00 |
$8,800,002 |
I/I |
463,158 |
463,158 |
1.5 |
- |
|
| Sibling Co-Investment Llc |
possible member of 10% group |
– – • |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
6,612,402 |
599,379 |
|
- |
|
| Hadley Harbor Master Investors (cayman) Ii L.p. |
10% Owner |
– – • |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,138,351 |
2,138,351 |
|
- |
|
| Alpern Robert J |
|
• • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,632 |
179,511 |
|
- |
|
| Veitinger Klaus R Dr |
|
• • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,632 |
39,436 |
|
- |
|
| Hirsch David |
|
• • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,632 |
3,632 |
|
- |
|
| Hirsch David |
|
• • – |
2018-07-02 |
4 |
B |
$19.00 |
$2,500,001 |
I/I |
131,579 |
3,019,734 |
0.01 |
- |
|
| Hirsch David |
|
• • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,888,155 |
2,888,155 |
|
- |
|
| Coufal Sandra I |
|
• • • |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,632 |
217,199 |
|
- |
|
| Coufal Sandra I |
|
• • • |
2018-07-02 |
4 |
B |
$19.00 |
$8,800,002 |
I/I |
463,158 |
463,158 |
0.01 |
- |
|
| Coufal Sandra I |
|
• • • |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
6,612,402 |
599,379 |
|
- |
|
390 Records found
|
|
Page 15 of 16 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
